Publications by authors named "Hiroki Taguchi"

Aneurysms in the V1 segment of the extracranial vertebral artery are extremely rare. Furthermore, half of the cases are giant aneurysms larger than 25 mm. This study reports a case of unruptured giant V1 aneurysm of the right vertebral artery that was successfully treated with endovascular coil embolization.

View Article and Find Full Text PDF

Anti-cancer drug cisplatin (CDDP) causes severe acute kidney injury (AKI). CDDP-induced AKI does not occur immediately after administration, but rather 6 to 10 days after administration. However, the mechanism underling the delayed renal injury by CDDP is not well understood.

View Article and Find Full Text PDF

Chronic exposure to arsenic has been shown to induce carcinogenesis in multiple organs, but the mechanisms underlying the multi-organ carcinogenicity of arsenic remain unknown. We here examined whether arsenic affects the amount of sialic acid on the cellular surface of immortalized HaCaT cells rather than cancerous cells to clarify the process of arsenic-induced carcinogenesis, since sialic acid is known to assist cancer cells in suppressing attacks by natural killer (NK) cells. Our results indicated that exposure to arsenite (As(III)) increases the amounts of sialic acid on the cell surface of HaCaT cells.

View Article and Find Full Text PDF

Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate marker of OS in pancreatic cancer chemotherapy focusing on FOLFIRINOX or GEM plus nab-paclitaxel remains unknown. We aimed to verify whether PFS can be a surrogate marker of OS in prognosis prediction.

View Article and Find Full Text PDF
Article Synopsis
  • EUS-guided biliary drainage (EUS-BD) has shown good results in high-volume centers, but this study investigates its safety and effectiveness in newer centers that recently adopted the procedure.
  • The research involved 22 centers from 2017 to 2022, assessing 255 patients and looking at the success and complications of EUS-BD performed by 84 endoscopists.
  • The study found a high technical success rate of 91.4% but identified specific risks for failure and complications, including smaller puncture target diameters and moderate ascites, highlighting that the experience level of endoscopists did not significantly affect outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • - This study compared the effectiveness of second-line treatments for patients with unresectable pancreatic cancer who previously received gemcitabine plus nab-paclitaxel (GnP), analyzing 318 patients treated with nanoliposomal irinotecan plus 5-fluorouracil/folinic acid (NFF), S-1, or FOLFIRINOX.
  • - Results showed that the median overall survival (OS) for the NFF group was significantly better at 9.08 months compared to 4.90 months for S-1, while FOLFIRINOX had an OS of 4.77 months with no significant difference from NFF.
  • - Factors like serum levels and duration
View Article and Find Full Text PDF

Cisplatin (CDDP) is administered as an anticancer drug across a broad spectrum of cancer treatments, but it causes severe renal damage. Several studies have attempted to elucidate the cause of CDDP-induced renal injury, but the detailed mechanism remains unclear. We previously found that S3 cells are more sensitive to CDDP than S1 and S2 cells by using immortalized cells derived from S1, S2, and S3 segments of proximal tubules.

View Article and Find Full Text PDF

Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy and safety in the real-world. We therefore initiated a retrospective and prospective observational study (NAPOLEON-2).

View Article and Find Full Text PDF

First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in clinical practice is still unknown. Data was gathered from 14 hospitals in the Kyushu area of Japan from December 2013 to March 2017.

View Article and Find Full Text PDF

Arsenic (+3 oxidation state) methyltransferase is an enzyme responsible for arsenic methylation, and it requires S-adenosyl-methionine (SAM) as a coenzyme. We here generated two mutants to clarify the role of the highly conserved 83rd arginine residue (Arg83) in Motif I, the SAM-binding domain, of human AS3MT. When the AS3MT activity was compared between the mutants and the wild type (WT) recombinant protein, little activity was detected in the glycine mutant (Arg83Gly) or lysine mutant (Arg83Lys).

View Article and Find Full Text PDF

We here examined whether CHAC1 is implicated in arsenite (As(III))-induced cytotoxicity in HaCaT cells. We found that HaCaT cells in which the intracellular GSH levels were elevated by transfection with CHAC1 siRNA showed decreased sensitivity to As(III) compared to the control cells. Treatment with BSO (an inhibitor of GSH biosynthesis) abolished the decrease in sensitivity to As(III), suggesting that an increase in intracellular GSH levels was involved in the decrease in sensitivity to As(III) due to the decrease in the levels of CHAC1 expression.

View Article and Find Full Text PDF

. Photon counting CT (PCCT) has been a research focus in the last two decades. Recent studies and advancements have demonstrated that systems using semiconductor-based photon counting detectors (PCDs) have the potential to provide better contrast, noise and spatial resolution performance compared to conventional scintillator-based systems.

View Article and Find Full Text PDF
Article Synopsis
  • Limited biomarkers exist for predicting prognosis in unresectable pancreatic cancer patients undergoing chemotherapy.
  • A study of 255 patients found that lower C-reactive protein/albumin ratio (CAR) and several other inflammatory markers were linked to better overall survival (OS) in first-line treatment.
  • CAR was identified as the most effective prognostic indicator, suggesting it could serve as a valuable biomarker for assessing patient outcomes in both first- and second-line chemotherapy.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with metastatic pancreatic cancer who do not respond to first-line chemotherapy have limited treatment options, and it's uncertain which patients benefit from second-line chemotherapy.
  • A study involving 233 patients analyzed the effectiveness of second-line chemotherapy compared to best supportive care, using a scoring system based on specific prognostic factors like serum albumin and CA19-9 levels.
  • Results showed that patients with scores of 0 and 1 had a significant survival benefit from second-line chemotherapy, while those with score 2 did not experience similar advantages.
View Article and Find Full Text PDF

Background/aim: Recent advances in chemotherapy have made significant progress in conversion surgery (CS) for unresectable pancreatic cancer (uPC). However, the success rate and efficacy of CS have not been fully demonstrated in patients with uPC treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP).

Patients And Methods: We retrospectively reviewed the records of 318 patients with uPC who received FFX or GnP as first-line chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Metal stents (MSs) show a lower incidence of recurrent biliary obstruction (RBO) compared to plastic stents (PSs) in procedures like EUS-guided hepaticogastrostomy (EUS-HGS) and choledochoduodenostomy (EUS-CDS).
  • A study involving 138 patients found that the use of PSs was linked to higher RBO rates, with MSs providing longer median times before obstruction occurred.
  • The results suggest that MSs are more effective than PSs in reducing RBO for both EUS-HGS and EUS-CDS procedures.
View Article and Find Full Text PDF
Article Synopsis
  • The study compares the efficacy and toxicity of the original FOLFIRINOX (oFFX) and a modified version (mFFX) for treating metastatic pancreatic cancer (mPC) in a Japanese patient population.
  • A multicenter analysis of 318 patients revealed no significant difference in overall survival and progression-free survival between oFFX and mFFX, although oFFX had higher rates of thromobocytopenia and liver dysfunction.
  • The findings suggest that mFFX is as effective as oFFX while causing fewer side effects, making it a safer option in clinical practice.
View Article and Find Full Text PDF
Article Synopsis
  • A new prognostic nomogram has been created to predict survival in Japanese patients with unresectable pancreatic cancer undergoing treatments with gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX.
  • The analysis involved 318 patients and identified key factors influencing survival such as performance status, liver metastasis, and specific serum markers.
  • The nomogram showed strong predictive ability with C-indexes ranging from 0.70 to 0.77 for different survival milestones, helping categorize patients into low, moderate, and high-risk groups based on survival times (15.8, 12.8, and 7.8 months, respectively).
View Article and Find Full Text PDF

Objectives: The aim was to investigate triage methods for suspected transient ischemic attacks (TIAs) with focal or nonfocal symptoms.

Materials And Methods: In total, 350 patients with suspected TIAs were enrolled and followed for one year. Potential high-risk factors for TIAs, such as atrial fibrillation, carotid artery stenosis, crescendo TIA, and ABCD2 score ≥ 4, were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) are both standard first-line treatments for advanced pancreatic cancer, but there has been no prior comparison of their effectiveness.
  • A retrospective study, called the NAPOLEON study, analyzed data from patients treated with either FFX or GnP to assess their efficacy and safety.
  • Results indicated similar median overall and progression-free survival rates between the two treatments, though FFX was associated with more severe anorexia compared to GnP, suggesting different toxicities that may influence treatment choice.
View Article and Find Full Text PDF

Background/aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection.

Patients And Methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed.

Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.

View Article and Find Full Text PDF
Article Synopsis
  • * A total of 153 patients were analyzed, showing no significant differences in adverse events or tumor response rates between age groups; however, older patients received lower doses of the treatment.
  • * The results indicated that GnP is a viable option for older patients, with similar rates of progression-free and overall survival compared to younger patients, while also suggesting that the Geriatric Nutrition Risk Index (GNRI) can help identify those at greater risk for poor outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • A 74-year-old woman experienced motor aphasia and was diagnosed with an intracerebral hemorrhage (ICH) linked to a developmental venous anomaly (DVA) with a stenosed collecting vein.
  • * Imaging techniques like CT and MRI revealed ICH in the left frontal lobe and showed DVA alongside a cavernous malformation (CM).
  • * Management focused on blood pressure control, and the patient did not suffer any further neurological issues; however, it was noted that DVA could lead to chronic venous hypertension and increased risk of hemorrhage if there is restricted outflow.
View Article and Find Full Text PDF

Renal toxicants such as cisplatin and cadmium cause segment-specific damages in kidney proximal tubules. Recently, we established an in vitro experimental system for evaluating segment-specific toxicity and transport of chemicals using immortalized S1, S2, and S3 cells derived from the S1, S2, and S3 regions of mouse kidney proximal tubules. In the present study, we examined the toxicity and accumulation of cisplatin, carboplatin, oxaliplatin, and cadmium in S1, S2, and S3 cells.

View Article and Find Full Text PDF